Print  |  Close

Northwest Georgia Oncology Centers - Marietta

We’re committed to FIGHTING FOR YOU.   The cancer care and treatment experts at Northwest Georgia Oncology Centers, P.C. (NGOC) collaboratively work to provide patients with the most advanced cancer treatment options available in Georgia at cancer centers in Austell, Bremen, Carrollton, Cartersville, Douglasville, Jasper, Marietta, Paulding, and Villa Rica.  NGOC oncologists are actively involved in cancer research through clinical trials, the treatment of difficult cancer cases and public policy to ensure people in Georgia have access to the best community-based cancer care. NGOC is a member of the Georgia CORE Research Network, a statewide network of academic and community-based oncologists and researchers and is a Commission on Cancer Accredited Oncology Medical Home.  For more information about NGOC cancer center locations and patient services, visit www.ngoc.com.

Treatment Sites in Georgia

Clinical Trials in Georgia

A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy
Cancer Type: Lung Cancer

A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine / Cisplatin Versus Placebo Plus Gemcitabine / Cisplatin as First-Line Therapy in Participants With Advanced and / or Unresectable Biliary Tract Carcinoma
Cancer Type: Unspecified

A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-agent Maintenance Versus Rituximab Maintenance in Subjects With Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma
Cancer Type: Non-Hodgkin Lymphoma
Study Coordinator: Mary Gilley - 770-281-5131


A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type: Ovarian Cancer
Study Coordinator: Mary Gilley - 770-281-5131


A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Cancer Type: Unspecified

A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Cancer Type: Lymphoma

An Open-Label, Multicenter Extension Study of Trastuzumab-MCC-DM1 (T-DM1) Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Treated With the Equivalent T-DM1 Regimen in a Genentech and/or F. Hoffmann-La Roche Ltd.-Sponsored T-DM1 Study
Cancer Type: Breast Cancer
Study Coordinator: Mary Gilley - (770) 281-5131


An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)
Cancer Type: Breast Cancer

Connect® MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Cancer Type: Leukemia
Study Coordinator: Mary Gilley - 770-281-5131


Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Cancer Type: Solid Tumor
Study Coordinator: Mary Gilley - 770-281-5131


Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Of Fulvestrant (Faslodex®) With Or Without PD-0332991 (Palbociclib) +/- Goserelin In Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy
Cancer Type: Breast Cancer
Study Coordinator: Mary Gilley - 770-281-5131
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.